Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
NAUT
STRONG SELLNautilus Biotechnology, Inc. · Healthcare · United States · $215M · Avg Vol: $2M/d
COMPANY DESCRIPTION
Nautilus Biotechnology, Inc. is a biotechnology company developing a transformative single-molecule protein analysis platform designed to revolutionize proteomics through ultra-sensitive, high-throughput, and quantitative protein detection. The company's competitive moat is based on its proprietary protein sequencing technology, which holds the potential to provide unprecedented insights into the proteome, thereby significantly advancing biological research and drug discovery. Nautilus is an innovative, early-stage player with the ambition to disrupt the proteomics market.
FINANCIAL SUMMARY (USD)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | 0 | 0 | 0 | 0 | — | — | 0.7M | 7.7M | — |
| EPS | -0.60 | -0.46 | -0.51 | -0.56 | -0.47 | — | -0.44 | -0.52 | -0.52 | — |
| Shares | — | 124.9M | 125.1M | 126.1M | 126.5M | +1.3% | 127.1M | — | — | — |
| Debt | — | 30.3M | 34.6M | 30.5M | 30.0M | -0.3% | 28.9M | — | — | — |
| Equity | — | 314.9M | 265.4M | 208.7M | 157.0M | -20.7% | — | — | — | — |
| Op CF | — | -45.8M | -51.7M | -59.1M | -50.7M | — | -49.9M | — | — | — |
| Inv CF | — | -25.7M | -43.7M | 66.3M | 35.2M | — | — | — | — | — |
| Fin CF | — | 0.6M | 0.4M | 1.1M | 0.2M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of NAUT are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| NAUT | Nautilus Biotechnology, Inc.(you) | $215M | 15 | STRONG SELL |
| SRZN | Surrozen, Inc. | $229M | 15 | STRONG SELL |
| CHRS | Coherus Oncology, Inc. | $217M | 17 | STRONG SELL |
| FULC | Fulcrum Therapeutics, Inc. | $248M | 14 | STRONG SELL |
| VYGR | Voyager Therapeutics, Inc. | $187M | 15 | STRONG SELL |
| RNA | Atrium Therapeutics, Inc. | $197M | 16 | STRONG SELL |
| IRD | Opus Genetics, Inc. | $254M | 14 | STRONG SELL |
| TARA | Protara Therapeutics, Inc. | $226M | 12 | STRONG SELL |
| RNAC | Cartesian Therapeutics, Inc. | $232M | 12 | STRONG SELL |
| NERV | Minerva Neurosciences, Inc. | $188M | 16 | STRONG SELL |
Peer medians: ROE -25.5% · P/E 27.6x · Gross margin 50.6%